http://eurheartj.oxfordjournals.org/content/37/14/1096.extract?etoc
…and the full paper!
International DCB Group Position Paper for lower extremities PTA
Sirolimus-coated Balloon: FIRST HUMAN USE
Great news-a few days ago I had the chance to use a sirolimus-coated balloon for coronary PCI in the first european patient (to say the truth, the first patient of the western world)!!
This very promising device just obtained the CE Mark for this application. A long way is ahead and I am really excited to be part of this adventure in designing a strict scientific program on the matter. In fact, no one wants to repeat the mistakes of the paclitaxel-eluting technology, that has only now reached a reliable scientific background.
CLIC meeting at Caltanissetta, Sicily
A couple of weeks ago, I had the pleasure to be invited at the CLIC, a cardiovascular meeting organized by Dr Amico in Caltanissetta. The event had the scientific background of some renown physicians from the group of Prof Tamburino in Catania, and I had the pleasure to be the only “continental” physician invited!
The meeting was of high scientific level and the discussion was interactive and interesting.
I contributed with a speech entitled “Incomplete revascularization and drug-coated balloons”, a setting where DCB may have a specific role. I also gave some contributions regarding biovascular scaffolds during the discussion. Give a look at the nice pics.
The Elutax SV Registry
This is the preliminary presentation of the results of the Elutax SV registry, a retrospective, national registry that is investigating the performance of a new-generation DCB for any coronary indications.
The role of DCB for recurrent ISR
Which is the most valuable treatment for recurrent in-stent restenosis, namely the ISR of 2 already implanted stents? We investigated the role of drug-coated balloons in this setting, and our findings seem to show how this strategy should be considered.